Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ABUS · as of Jun 8, 2026
Key Statistics
Explore Arbutus Biopharma Corporation Data
abus stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 80.0%
The ABUS analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $8.50, representing +101.54% upside from the current price of $4.22.
Competitors & Peers
abus competitorsABUS
BCAX
EYPT
GHRS
KURA
NBTXStock Performance
Full HistoryAbout Arbutus Biopharma Corporation
Arbutus Biopharma Corporation a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV…
what is arbutus biopharma corporation · abus stock overview · arbutus biopharma corporation company profile · who is arbutus biopharma corporation ceo · abus NASDAQ · arbutus biopharma corporation headquarters · arbutus biopharma corporation business segments
About Stock Overview & Key Data
Arbutus Biopharma Corporation (ABUS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 26, 2007. As of the latest trading session, ABUS stock price is $4.22, with a market capitalization of $833.6M. The stock has returned +20.23% over the past 12 months and -12.27% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Arbutus Biopharma Corporation stock is Buy, with an average 12-month price target of $8.50. In fiscal year 2025, Arbutus Biopharma Corporation reported revenue of $14.1M and net income of -$33.5M. For detailed data — including Arbutus Biopharma Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Arbutus Biopharma Corporation (ABUS) stock price is $4.22. The stock is traded on NASDAQ under the ticker symbol ABUS. The 52-week range is $3.04 – $5.10.